Short CommunicationSimultaneous Quantitative Assay of Atazanavir and 6 Other HIV Protease Inhibitors by Isocratic Reversed-Phase Liquid Chromatography in Human PlasmaTribut, Olivier*; Verdier, Marie-Clémence*; Arvieux, Cédric†; Allain, Hervé*; Michelet, Christian†; Bentué-Ferrer, Danièle*Author Information From the *Laboratoire de Pharmacologie, Hôpital de Pontchaillou, 35033 Rennes, France; and †Service des Maladies Infectieuses, Hôpital de Pontchaillou, 35033 Rennes, France. Received for publication July 15, 2004; accepted February 25, 2005. Reprints: O.Tribut, Laboratoire de Pharmacologie, Hôpital de Pontchaillou, 2 rue Henri Le Guilloux, 35033 Rennes, France (e-mail: [email protected]). Therapeutic Drug Monitoring: June 2005 - Volume 27 - Issue 3 - p 265-269 doi: 10.1097/01.ftd.0000162230.83188.32 Buy Metrics Abstract Several liquid chromatography methods for assay of antiretroviral drugs in human plasma have been described, but none included atazanavir. The authors describe a user-friendly, validated, and rapid technique, derived from a procedure the authors have already published, allowing simultaneous quantification of amprenavir, indinavir, lopinavir, nelfinavir (and its M8 metabolite), ritonavir, saquinavir, efavirenz, and nevirapine. Assays were performed after diethyl ether liquid-liquid extraction from 250 μL plasma samples. Chromatographic separation was achieved on an X-TERRA column using a 58% water (with 3 mM pyrrolidine) and 42% acetonitrile mobile phase; 240 nm ultraviolet wavelength was used for atazanavir detection. This method has been in routine use in our laboratory for antiretroviral drug monitoring and now allows quantitative assay of a novel HIV protease inhibitor, atazanavir, with satisfactory intra- and interassay precision (CV < 12%). © 2005 Lippincott Williams & Wilkins, Inc.